Evidence map›Paper›PMID 38736183›Full record

ArticleNeuropathology : official journal of the Japanese Society of Neuropathology2025

Somatic mutational profiling and clinical impact of driver genes in Latin-Iberian medulloblastomas: Towards precision medicine.

Letícia Ganem Rillo Paz Barateiro, Rodrigo de Oliveira Cavagna, Mariana Bisarro Dos Reis, Flávia Escremim de Paula, Gustavo Ramos Teixeira, Daniel Antunes Moreno, Murilo Bonatelli, Iara Santana, Fabiano Pinto Saggioro, Luciano Neder and 10 more

Abstract read
In one paragraph

Article in Neuropathology : official journal of the Japanese Society of Neuropathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Letícia Ganem Rillo Paz BarateiroMolecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.
Rodrigo de Oliveira CavagnaMolecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.ORCID https://orcid.org/0000-0001-9069-1295
Mariana Bisarro Dos ReisMolecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.
Flávia Escremim de PaulaMolecular Diagnostic Laboratory, Barretos Cancer Hospital, Barretos, Brazil.
Gustavo Ramos TeixeiraMolecular Diagnostic Laboratory, Barretos Cancer Hospital, Barretos, Brazil.
Daniel Antunes MorenoMolecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.ORCID https://orcid.org/0000-0002-0764-447X
Murilo BonatelliMolecular Diagnostic Laboratory, Barretos Cancer Hospital, Barretos, Brazil.
Iara SantanaDepartment of Pathology, Barretos Cancer Hospital, Barretos, Brazil.
Fabiano Pinto SaggioroRibeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Luciano NederRibeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
João Norberto StavaleFederal University of São Paulo, São Paulo, Brazil.
Suzana Maria Fleury MalheirosFederal University of São Paulo, São Paulo, Brazil.
Hernan Garcia-RivelloItalian Hospital of Buenos Aires, Buenos Aires, Argentina.
Silvia ChristiansenItalian Hospital of Buenos Aires, Buenos Aires, Argentina.
Susana NunesSão João Hospital, Porto, Portugal.
Maria João Gil da CostaSão João Hospital, Porto, Portugal.
Jorge PinheiroSão João Hospital, Porto, Portugal.
Carlos Almeida JúniorPediatric Department, Barretos Cancer Hospital, Barretos, Brazil.
Bruna Minniti MançanoPediatric Department, Barretos Cancer Hospital, Barretos, Brazil.
Rui Manuel ReisMolecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.ORCID https://orcid.org/0000-0002-9639-7940

Funding

Brazilian Ministry of Health (MoH)Brazilian National Program of Genomics and Precision Health 16/2023Conselho Nacional de Desenvolvimento Científico e TecnológicoCoordenação de Aperfeiçoamento de Pessoal de Nível SuperiorCoordination for the Improvement of Higher Education PersonnelFundação de Amparo à Pesquisa do Estado de São PauloHospital de Câncer de BarretosPublic Ministry of Labor CampinasSão Paulo Research Foundation 2021/13861-0the National Council for Scientific and Technological Development
6 · The paper itself

Abstract

Medulloblastoma (MB) is the most prevalent malignant brain tumor in children, known for its heterogeneity and treatment-associated toxicity, and there is a critical need for new therapeutic targets. We analyzed the somatic mutation profile of 15 driver genes in 69 Latin-Iberian molecularly characterized medulloblastomas using the Illumina TruSight Tumor 15 panel. We classified the variants based on their clinical impact and oncogenicity. Among the patients, 66.7% were MB

Indexed as

Cerebellar NeoplasmsMedulloblastomaAdolescentChildChild, PreschoolFemaleHumansInfantMaleMutationPrecision MedicineYoung Adultmedulloblastomamutational profilenext‐generation sequencingprecision medicinesomatic variants

Identifiers

PMID38736183
PMCPMC11788001

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.